Talphera, Inc. (TLPH)
TLPHNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.09
+0.0300 (+2.83%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $56.58m
- P/E
- –
- EPS, last 4 quarters
- $-0.2700
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.6866 to $1.57
- Average volume
- 106.2k
- Previous close
- $1.06
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $3.00, +175.2% from here
Earnings
next estimate $-0.0600Next report Nov 12, 2026
Sep 2025
–
Dec 2025
–
Mar 2026
–
Jun 2026
+14.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1,000 | – | – | – |
| Gross profit | $1,000 | – | – | – |
| Operating income | -$3.42m | -$3.45m | -$3.95m | -$3.92m |
| Net income | -$4.44m | -$3.77m | -$2.56m | -$4.31m |
News
8 latest- Talphera (TLPH) Upgraded to Buy: Here's What You Should KnowZacks · Sep 21, 2026
- Talphera (TLPH) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 19, 2026
- Talphera Q2 Earnings Call HighlightsMarketBeat · Aug 12, 2026
- Talphera Reports Q1 Loss Of $2 Mln; Completes 50% Enrolment In Phase 3 Trial RTTNews · May 19, 2026
- Talphera (TLPH) Q1 2026 Earnings TranscriptThe Motley Fool · May 13, 2026
- WestPark Capital Initiates Coverage of Talphera (TLPH) with Buy RecommendationFintel · Apr 30, 2026
- After-Hours Surge: Turn Therapeutics Rockets 134% Post-Close On Nasdaq Debut; Biotech Stocks Rally RTTNews · Oct 9, 2025
- Talphera Announces $29 Mln Private Placement Led By CorMedix And Institutional Investors RTTNews · Sep 8, 2025
The company
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- talphera.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.